Based on the network pharmacology approach, the core active constituents including naringenin and ferulic acid, as well as core targets such as ALB, TNF, IL6, and VEGFA were screened for YLTZC for the treatment of HLP. This evidence concerns the gene TNF and hyperkeratosis lenticularis perstans.